In a much-needed bit of good news for the Huntington's disease community, Neurocrine Bioscience's KINECT-HD trial showed that treatment with valbenazine significantly reduced the involuntary movements called chorea. For more information, watch the below video. If you're interested in enrolling in the trial, check out more at the Huntington Study Group.

Watch Video

The Research Video Series is in partnership with HD Buzz and sponsored by Genentech and Sage Therapeutics.